Results 111 to 120 of about 1,381,406 (265)
, 2015 Pulmonary hypertension (PH) is a haemodynamic condition that leads to a progressive increase in pulmonary vascular resistance and mean pulmonary artery pressure.
Vonk Noordegraaf, Anton +3 more
core +1 more source
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Arthritis &Rheumatology, EarlyView.Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti +52 more
wiley +1 more source
The Novel Treatment Options For Pulmonary Arterial Hypertension
, 2021 Pulmonary arterial hypertension is a life threating disease.prior to therapy development the disease mortality was very high and prognosis was poor.
Dahbour, May
core
Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)
British Journal of Clinical Pharmacology, EarlyView.Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul +7 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseasePulmonary arterial hypertension is a disease of the pulmonary vasculature, resulting in elevated pressure in the pulmonary arteries and disrupting the physiological coordination between the right heart and the pulmonary circulation.
Thaís C. F. Menezes +8 more
doaj +1 more source
The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension
, 2016 Chronic thromboembolic pulmonary hypertension (CTEPH) is a late sequel of venous thromboembolism that cannot be completely reproduced in animal models. The prevalence of CTEPH in humans is estimated at roughly 17-20 per million; however, partly because ...
Vonk Noordegraaf, Anton +5 more
core +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
British Journal of Clinical Pharmacology, EarlyView.Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
Pulmonary Circulation, 2019 In order to intervene appropriately and develop disease-modifying therapeutics for pulmonary arterial hypertension, it is crucial to understand the mechanisms of disease pathogenesis and progression.
Edda Spiekerkoetter +10 more
doaj +1 more source
, 2015 Exclusion of pulmonary hypertension secondary to left-sided heart disease (left heart failure (LHF)) is pivotal in the diagnosis of pulmonary arterial hypertension (PAH). In case of doubt, invasive measurements are recommended.
Heymans, M.W. +6 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz +7 more
wiley +1 more source